SequelSEC

NEUROONE MEDICAL TECHNOLOGIES Corp NMTC

Surgical & Medical Instruments & Apparatus · CIK 0001500198 · Fiscal year ends 0930

AnnualQuarterlyTTM
Revenue
$1.97M
Fiscal year ended 2026-06-30
Operating income
-$2.42M
Fiscal year ended 2026-06-30
Free cash flow
-$1.10M
Fiscal year ended 2026-06-30

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) reported revenue of $1.97M and net income of -$2.01M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from NEUROONE MEDICAL TECHNOLOGIES Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

NEUROONE MEDICAL TECHNOLOGIES Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$1.97M$1.86M$2.89M$2.74M$1.70M$1.39M$3.27M$272.28K$825.78K$1.38M
Cost of revenue$790.50K$871.79K$1.32M$1.21M$781.22K$615.49K$1.35M$131.22K$543.90K$986.88K
Gross profit$1.18M$990.26K$1.57M$1.53M$914.84K$771.06K$1.93M$141.06K$281.87K$390.42K
Operating income-$2.42M-$2.40M-$1.71M-$1.37M-$1.89M-$2.68M$1.71M-$2.82M-$2.79M-$2.89M
Net income-$2.01M-$2.38M-$1.44M-$1.62M-$1.50M-$2.27M$1.79M-$3.35M-$2.77M-$2.86M
Research & development$1.43M$1.47M$1.39M$1.12M$1.18M$1.51M$1.17M$1.11M$1.19M$1.27M
Weighted-average diluted sharesshares 8.74Mshares 8.48Mshares 50.33MUnavailableshares 8.10Mshares 5.19Mshares 30.88MUnavailableshares 27.35Mshares 25.91M
Pretax income-$2.01M-$2.38M-$1.44M-$1.62M-$1.50M-$2.27M$1.79M-$3.35M-$2.77M-$2.86M
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.28$-0.28$-0.03Unavailable$-0.19$-0.44$0.06Unavailable$-0.10$-0.11
Selling, general & administrative$2.18M$1.92M$1.89M$1.78M$1.62M$1.94M$2.04M$1.84M$1.88M$2.00M
General & administrative$1.69M$1.50M$1.45M$1.35M$1.26M$1.58M$1.65MUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

NEUROONE MEDICAL TECHNOLOGIES Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$2.05M$2.80M$3.56M$6.57M$8.04M$1.32M$1.13M$1.46M$1.62M$2.43M
Total assets$6.19M$7.57M$8.58M$10.79M$10.82M$4.46M$6.49M$5.37M$4.91M$5.39M
Current assets$5.79M$7.11M$8.07M$10.23M$10.17M$3.75M$5.71M$4.63M$4.09M$4.71M
Total liabilities$2.42M$2.49M$2.18M$3.71M$2.64M$3.33M$3.56M$4.55M$1.90M$1.54M
Current liabilities$2.04M$1.69M$1.26M$2.30M$1.43M$1.76M$1.57M$2.21M$1.69M$1.54M
Total equity incl. NCI$3.77M$5.08M$6.40M$7.07M$8.18M$1.13M$2.94M$822.01K$3.01M$3.85M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$2.29M$2.10M$1.67M$2.23M$1.90M$1.83M$1.93M$2.64M$1.79M$1.31M
Accounts receivable$1.10M$1.90M$2.66M$1.26MUnavailable$318.78K$2.37M$176.64K$410.55K$555.64K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$905.72K$934.20K$552.33K$1.01M$467.73K$910.75K$744.52K$1.03M$759.26K$780.84K

Cash flow

NEUROONE MEDICAL TECHNOLOGIES Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$1.08M-$1.33M-$3.12M-$1.53M-$1.46M-$56.14K$208.05K-$2.67M-$2.36M-$2.18M
Capital expenditures$19.66K$38.52K$40.75K$10.61K$43.55K$3.17K$24.42K$36.90K$14.80K$31.36K
Investing cash flow-$19.66K-$38.52K-$40.75K-$10.61K-$43.55K-$3.17K-$24.42K-$36.90K-$14.80K-$31.36K
Financing cash flow$345.03K$609.62K$147.82K$66.98K$8.23M$245.22K-$509.32K$2.54M$1.56M$1.96M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$352.78K$342.14K$359.26K$358.56K$316.65K$250.17K$339.22K$340.37K$338.61K$356.86K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$47.00K$60.03K$65.52K$64.32K$66.59K$65.63K$65.13K$64.13K$63.11K$60.90K

Derived

NEUROONE MEDICAL TECHNOLOGIES Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$1.10M-$1.37M-$3.16M-$1.54M-$1.51M-$59.32K$183.63K-$2.70M-$2.38MUnavailable
Gross margin59.9%53.2%54.2%55.8%53.9%55.6%58.9%51.8%34.1%28.3%
Operating margin-122.9%-128.7%-59.0%-50.0%-111.2%-193.3%52.3%-1034.5%-338.3%-209.5%
FCF margin-55.8%-73.4%-109.1%-56.0%-88.9%-4.3%5.6%-993.0%-287.6%Unavailable
SBC / revenue17.9%18.4%12.4%13.1%18.7%18.0%10.4%125.0%41.0%25.9%
Current ratio2.84x4.21x6.41x4.44x7.13x2.13x3.64x2.09x2.42x3.06x
Revenue YoY growth16.3%34.3%-11.7%906.6%105.4%0.7%234.9%-63.3%31.1%195.4%
Net margin-101.7%UnavailableUnavailable-59.1%-88.5%UnavailableUnavailable-1230.6%-335.1%Unavailable
R&D / revenue72.2%78.8%48.0%40.8%69.7%109.0%35.8%409.0%144.7%92.5%
CapEx / revenue1.0%2.1%1.4%0.4%2.6%0.2%0.7%13.6%1.8%Unavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NMTC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q/A · Filed 2026-06-12View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-Q · Filed 2026-02-17View SEC filing
10-K · Filed 2025-12-17View SEC filing
10-Q · Filed 2025-08-14View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.